Acquisition of Novavax CZ. (Tables)

9 Months Ended

Sep. 30, 2020

Acquisition of Novavax CZ

Summary of preliminary allocation of the Purchase Price based upon the fair values of assets acquired and liabilities assumed at the Acquisition Date

The preliminary allocation is based upon information that was available to management at the time the consolidated financial statements were prepared and is subject to change prior to completion of the measurement period (in thousands):

Prepaid expense and other current assets	$	326
Property and equipment		96,739
Goodwill		70,662
Accounts payable		(1,193)
Accrued expenses		(205)
Other non-current liabilities		(813)
Purchase Price, net of cash acquired	$	165,516

Summary of unaudited pro forma financial information

The unaudited pro forma financial information combines the historical results of operations of the Company and Novavax CZ for the periods presented below and reflects the application of certain pro forma adjustments (in thousands, except per share amounts):

	Three Months Ended				Nine Months Ended
	September 30, 2020				September 30,
	2020		2019		2020		2019
Revenue	$	157,024	$	2,507	$	195,939	$	9,846
Net loss		(196,590)		(19,982)		(242,411)		(107,349)
Basic and diluted net loss per share		(3.19)		(0.45)		(4.21)		(2.51)